– Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months – – Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evorpacept activity and drives durable benefit in HER2-positive cancers – – Full biomarker analysis from Phase 1b/2 evorpacept-zanidatamab combination trial accepted for poster presentation at ESMO Breast Cancer 2026 Annual Congress – – Phase 2 ASPEN-09 breast cancer trial is currently enrolling patients and will evaluate...

BALLERUP, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) — LiqTech International, Inc. (Nasdaq: LIQT) (“LiqTech”), a clean technology company that manufactures and markets highly specialized filtration technologies, today announces its financial results for the fourth quarter and fiscal year 2025 for the period ended December 31, 2025. Recent Financial HighlightsFY 2025 revenue of $16.5 million, a 13% increase from $14.6 million in FY 2024. Q4 2025 revenue of $3.1 million, compared to $3.4 million in Q4 2024, an 8% decrease. FY 2025 net loss of $(8.6) million compared to $(10.3) million in FY 2024. Q4 2025 net loss of $(2.6) million compared to $(3.0) million in Q4 2024. FY 2025 Adjusted EBITDA of $(5.0) million compared to $(6.1) million in FY 2024. Ending cash balance of $5.1 million on December 31, 2025.OutlookThe...

MONTREAL, Feb. 27, 2026 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the fourth quarter and fiscal 2025. Highlights Financial resultsProduction and net earnings higher in Q4-2025Quarterly production up 18% (17% on a Combined1 basis)2 from Q4-2024, owing mainly to favourable wind conditions and the impact of newly commissioned sites, and 5% (7%) below anticipated production1. Production for fiscal 2025 is up 8% (8%) from 2024 and 8% (10%) below anticipated production; Operating income of $68 million ($85 million) in Q4-2025, down $10 million (up $32 million)3 from Q4-2024; operating income of $166 million ($248 million) for fiscal 2025, down $60 million ($19 million) from 2024; EBITDA(A)1 of $178 million ($203 million) in Q4-2025, up $9 million ($12 million)...

HOUSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) — Natural Resource Partners L.P. (NYSE:NRP) today reported fourth quarter and full year 2025 results as follows:    For the Three Months Ended     For the Year Ended  (In thousands) (Unaudited)   December 31, 2025  Net income   $ 30,998     $ 136,367  Operating cash flow   $ 44,765     $ 165,863  Free cash flow(1)   $ 45,508     $ 168,748  ____________________  (1 ) See “Non-GAAP Financial Measures” and reconciliation tables at the end of this release.2025 Highlights:Generated $169 million of free cash flow Retired $109 million of debt: $33 million of debt remaining Paid total distributions of $4.21 per common unit in 2025, consisting of $3.00 of regular distributions and a special cash distribution of $1.21 to help cover unitholder tax liabilities associated...

VANCOUVER, British Columbia, Feb. 27, 2026 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces its financial and operating results for the three months and year ended December 31, 2025. All dollar amounts are in US dollars ($). “2025 was a transformative year for Endeavour, marked by robust production growth, record revenues and key strategic milestones that have propelled the Company forward,” said Dan Dickson, Chief Executive Officer. “The successful commissioning of Terronera, the acquisition of Kolpa and the sale of Bolañitos Mine have not only enhanced the Company’s asset portfolio but also positioned it for sustained growth and long-term success.” “With a strong balance sheet, Endeavour has the financial flexibility to advance its strategic objectives and continue prioritizing...

Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectively Total Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectivelyQuarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectively Quarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9 million, respectively(1)Quarterly and full year GAAP net income available to common shareholders of $27.5 million and $77.2 million, respectively Record quarterly and full year adjusted non-GAAP EBITDA of $65.4 million and $229.8 million, up 30.6% and 47.3% year-over-year, respectively Quarterly diluted GAAP income per share of $1.18 and...

LOUISVILLE, Ky., Feb. 27, 2026 (GLOBE NEWSWIRE) — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the fourth quarter and full year ended December 31, 2025 and initiated full year 2026 Revenue and Adjusted EBITDA1 guidance. Fourth Quarter 2025 Financial Highlights(note: all figures represent continuing operations and exclude the Community Living business)Net revenue of $3,551 million, up 29.3% compared to $2,747 million in the fourth quarter of 2024 Gross profit of $413 million, up 21.8% compared to $339 million in the fourth quarter of 2024 Net income of $49.6 million compared to net income of $4.3 million in the fourth quarter of 2024 Adjusted EBITDA1 of $184 million,...

‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion; GAAP Net Income of $72 million; Diluted Income per Share of $0.22 ‒ ‒ Full Year 2025 Adjusted Net Income of $269 million; Adjusted EBITDA of $688 million; Adjusted Diluted EPS of $0.83 ‒ ‒ Provides 2026 Financial Guidance of $3.05 to $3.15 billion in net revenue, $720 to $760 million in Adjusted EBITDA, and $0.93 to $1.03 in Adjusted Diluted EPS – BRIDGEWATER, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”)...

MANAGEMENT REPORT Real Estate Development Tallinn During the fourth quarter of 2025 we completed the construction of the white building in our Uus- Kindrali project, located in Kristiine City, Tallinn. Client inspections and the signing of real rights agreements commenced in November, and by year-end, we had successfully closed 39 residential units in the white building. The remaining pre-sold units are scheduled to be closed during the first quarter of 2026. By the end of the reporting period, corresponding with the completion of construction, 78% of the sellable area (m²) had been sold. At the same time, the construction activities continued on a second seven-storey residential building with 90 units, located next to the white building at Sammu Street 10 / Seebi Street 24a, Tallinn. By the year end all the windows had been installed;...

MANAGEMENT REPORT Real Estate Development Tallinn During the fourth quarter of 2025 we completed the construction of the white building in our Uus- Kindrali project, located in Kristiine City, Tallinn. Client inspections and the signing of real rights agreements commenced in November, and by year-end, we had successfully closed 39 residential units in the white building. The remaining pre-sold units are scheduled to be closed during the first quarter of 2026.  By the end of the reporting period, corresponding with the completion of construction, 78% of the sellable area (m²) had been sold. At the same time, the construction activities continued on a second seven-storey residential building with 90 units, located next to the white building at Sammu Street 10 / Seebi Street 24a, Tallinn. By the year end all the windows had been installed;...